Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fabry disease
Biotech
Sangamo lays off 27% of US staff in latest refocus
A month after being abandoned by Biogen and Novartis, Sangamo is laying off 120 employees and refocusing on three key areas.
James Waldron
Apr 27, 2023 8:55am
FDA slaps hold on 4DMT's phase 1/2 gene therapy trial
Feb 3, 2023 1:28pm
4D's Fabry gene therapy flounders amid adverse events
Jan 11, 2023 10:15am
Avrobio hopes to get investors back on gene therapy bandwagon
Dec 7, 2022 7:30am
Sangamo shares post-ERT durability data on Fabry gene therapy
Oct 12, 2022 7:40am
Protalix eyes 2nd try at Fabry med in 2H22
Mar 18, 2022 9:22am